AzTrials
AzTrials

Liver CirrhosisNCT04494542

Sustained Low Efficiency Dialysis Versus Continuous Renal Replacement Therapy for Acute Kidney Injury in Critically Ill Cirrhotics

A study testing Sustained Low Efficiency Dialysis (SLED) and Continuous Renal Replacement Therapy in people with Liver Cirrhosis, run by Institute of Liver and Biliary Sciences, India at 1 site in India.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The current prospective pliot randomized controlled trial has been designed to demonstrate non-inferiority of sustained low efficiency dialysis (SLED) when compared to continuous renal replacement therapy in managing AKI in context of cirrhotics with septic shock who are hemodynamically unstable. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Liver Cirrhosis
What is being tested?
Sustained Low Efficiency Dialysis (SLED) and Continuous Renal Replacement Therapy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
62 participants
Where
1 siteIndia
Study dates
16 Oct 2020to 16 May 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Critically ill cirrhotics with septic shock defined as need of vasopressors to maintain MAP> 65 mm Hg and lacate >2 mmol/L despite adequate fluid resuscitation with severe AKI meeting criteria for dialysis

Who cannot join

  • Patients with age less than 18 years or more than 65 years
  • Severe known cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, COPD, CKD)
  • Patients with ACLF
  • Patients with cerebral edema
  • Patients with refractory shock i.e. requiring norepinephrine or equivalent >0.5ug/kg/min
  • Severe coagulopathy platelets <20,000 and INR >4
Show all 15Show fewer
  • Active Bleed (Mucosal or variceal)
  • Pregnancy
  • Patients with moderate-severe ARDS i.e. Pa02/Fio2 ratio <200
  • Extremely moribund patients with an expected life expectancy of less than 24 hours
  • Failure to give informed consent from family members.
  • Patient enrolled in other clinical trials
  • Patients with Hepatorenal Syndrome, post renal obstructive AKI, AKI suspected due to glomerulonephritis, interstitial nephritis or vasculitis based on clinical history and urine analysis
  • Patients who have already been on hemodialysis before their arrival in the intensive care unit
  • Patients with severe vasodilatation SVR <400 dyn·s/cm5 and/or lactate > 5 mmol/L

Trial locations and contacts

1 site in 1 country.

India1 site
  • Institute of Liver & Biliary Sciences

    New Delhi, National Capital Territory of Delhi, 110070

Other trials in India

About this study

Official title: Sustained Low Efficiency Dialysis Versus Continuous Renal Replacement Therapy for Acute Kidney Injury in Critically Ill Cirrhotics-A Pilot Randomized Controlled Trial.

The current prospective pliot randomized controlled trial has been designed to demonstrate non-inferiority of sustained low efficiency dialysis (SLED) when compared to continuous renal replacement therapy in managing AKI in context of cirrhotics with septic shock who are hemodynamically unstable. The patients would be randomized 1:1 to either SLED or CRRT after screening for the inclusion and exclusion criteria.

Read the detailed description

Aim \& Objectives

Primary objective To study the efficacy of sustained low efficiency dialysis versus continuous renal replacement therapy in cirrhotics with septic shock and severe AKI

Secondary Objectives Effects on renal recovery rates in the two groups To assess the effects on 7-day and 28-day mortality Efficacy on Lactate Clearance Duration of mechanical ventilation and ICU stay Effect on systemic hemodynamics and reversal of shock Clearance of endotoxin and pro-inflammatory cytokines Effect on coagulation and endothelial function Improvement in SOFA scores at 48 hours and day 5

Methodology All included patients would be randomised to receive either continuous renal replacement therapy or sustained low efficiency dialysis (SLED) Patients with septic shock would be screened. Following this, patients meeting the inclusion and exclusion criteria will be screened and randomized to the two treatment groups. Standard criteria will be considered to define refractoriness to fluids and initiation of dialysis. Fluid management would be performed using the dynamic indices in patients on mechanical ventilation or using IVC diameter and passive-leg rasing in non-intubated patients. In all patients, baseline endotoxin activity assay and blood and urine sample will be stored for looking at the effect of therapy on cytokine profile (TNF alpha, IL-IB, IL6, IFN-gamma, MCP-1, IL-10 and ADAMTS and vWillebrand factor). Septic shock would be defined as a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP>=65 mm of Hg and having a serum lactate >2 mmol/L despite adequate volume resuscitation. The blood flow rate, dialysis flow rate and need of ultrafiltration would be recorded for all enrolled patients. Subsequent sessions of therapy would be done as per requirement and recorded. The dose of vasopressor in norepinephrine equivalent would be recorded for all patients at enrolment as under

Study Population:

Patients with cirrhosis with septic shock and AKI requiring dialysis

Indications for initiation of dialysis

  1. Metabolic acidosis with ph<7.2 or serum bicarbonate <15 mEq/lt
  2. Hyperkalemia with serum potassium >5.5 Meq/L non-responsive to standard treatment
  3. Oliguria with or without fluid overload (non-responsive to diuretics) with urine output of less than 0.5ml/kg/hr despite fluid resuscitation
  4. Uremic complications (encephalopathy, pericarditis etc.)

Study Design:

  • A randomized controlled study- Non-inferiority trial
  • The study will be conducted on patients admitted to Department of Hepatology from June 2020 to December 2020 at ILBS, New Delhi
  • Study group will comprise critically ill patients with cirrhosis with septic shock and AKI requiring dialysis

Study Period: The study will be conducted on patients admitted to Department of Hepatology from May 2020 to December 2020 at ILBS, New Delhi

Sample Size Calculation: The study will be designed as a pilot RCT with an aim to enrol 25 patients in each group. At completion a decision for termination versus continuation of the study would be taken.

Intervention: CRRT versus SLED until renal recovery

Renal recovery would be defined as increase in urine output to more than 400ml/day in patients with anuria, resolution of metabolic complications or spontaneous decline in urea and creatinine necessitating stopping dialytic support

Monitoring and Assessment: Hourly till the patient is in the intensive care then every 7 days until day 28

Statistical analysis

  • All variables shall be expressed in mean (sd) or median (range)
  • Variables will be compared by Mann- Whitney U test
  • For Categorical variables we will use Chi-Square or Fisher's test
  • Survival analysis will be done using Cox-proportional regression analysis

Actuarial probability of survival shall be calculated by Kaplan- Meier graph and compared by log- rank test.

Adverse Effects: Worsening of hypotension, bleeding any cardiac side-effects, worsening lactate, hypothermia, bradycardia

Stopping Rule: clinically relevant bleeding (i.e., transfusion requirements of at least 2 units of packed red cells), arrythmias (brady or tachyarryhthmias), poorly tolerated supraventricular arrhythmia related blood stream infections, development of electrolyte abnormalities hypokalemia, hypophosphatemia or hypomagnesemia refractory to medical management, renal recovery

Conditions
Liver Cirrhosis
Being tested
Sustained Low Efficiency Dialysis (SLED), Continuous Renal Replacement Therapy
Medical subject headings
Liver Cirrhosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sustained Low Efficiency Dialysis (SLED)Procedure or surgery

    sustained low efficiency dialysis (SLED)

  • Continuous Renal Replacement TherapyProcedure or surgery

    Continuous Renal Replacement Therapy

Study groups in NCT04494542
Study groupRoleWhat they receive
Sustained Low Efficiency DialysisExperimentalSustained Low Efficiency Dialysis
Receives: Procedure: Sustained Low Efficiency Dialysis (SLED)
Continuous Renal Replacement TherapyActive comparatorcontinuous renal replacement therapy
Receives: Procedure: Continuous Renal Replacement Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Development of intradialytic hypotension i.e. decrease in defined as a decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by 10 mm Hg after initiation of dialysis

    Measured: at 6 hours after dialysis initiation

Secondary outcomes (7)
  1. Mortality in both groups

    Measured: Day 28

  2. Duration of mechanical ventilation and ICU stay

    Measured: Day 28

  3. AKI recovery at day 14

    Measured: Day 14

  4. Renal failure related death at day 7

    Measured: Day 7

  5. Lactate clearance at 12 in both groups

    Measured: 12 hours

  6. Lactate clearance at 24 hours in both groups

    Measured: 24 hours

  7. Reversal of shock at 48 hours

    Measured: 48 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2020
  2. Study start16 Oct 2020
  3. Primary completion16 May 2023
  4. Study completion16 May 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
62 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04494542
Sponsor's protocol ID
ILBS-Cirrhosis-36
Status last verified
Nov 2023
First submitted
28 Jul 2020
Last updated
3 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Sustained Low Efficiency Dialysis (SLED) and Continuous Renal Replacement Therapy in people with Liver Cirrhosis, run by Institute of Liver and Biliary Sciences, India at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Development of intradialytic hypotension i.e. decrease in defined as a decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by 10 mm Hg after initiation of dialysis (time frame: at 6 hours after dialysis initiation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2023; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in